Scarica l'app Stockscreener
6.0301
1.01%
0.0601
Precedente Chiudi:
$5.97
Aprire:
$6.01
Volume 24 ore:
39,455
Relative Volume:
0.34
Capitalizzazione di mercato:
$31.41M
Reddito:
$36.86M
Utile/perdita netta:
$-171.67M
Rapporto P/E:
-4.0201
EPS:
-1.5
Flusso di cassa netto:
$-171.05M
1 W Prestazione:
-14.35%
1M Prestazione:
-29.86%
6M Prestazione:
-62.62%
1 anno Prestazione:
-83.01%
Intervallo 1D:
$6.005
$6.31
Intervallo di 1 settimana:
$5.85
$7.00
Portata 52W:
$5.85
$70.75
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Nome
Mersana Therapeutics Inc
Settore
Industria
Telefono
617-498-0020
Indirizzo
840 MEMORIAL DRIVE, CAMBRIDGE
Confronta MRSN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
6.07 | 31.41M | 36.86M | -171.67M | -171.05M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.43 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
553.59 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.22 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
640.53 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
287.66 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-06 | Iniziato | William Blair | Outperform |
| 2024-11-15 | Ripresa | Citigroup | Buy |
| 2024-03-19 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2024-02-29 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2024-02-29 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-02-29 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-12-04 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-07-28 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2023-07-27 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-07-27 | Downgrade | Citigroup | Buy → Neutral |
| 2023-07-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-07-27 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-07-27 | Downgrade | Truist | Buy → Hold |
| 2023-07-27 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-06-16 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-06-15 | Iniziato | Guggenheim | Buy |
| 2023-03-16 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-01-20 | Iniziato | Citigroup | Buy |
| 2022-11-21 | Iniziato | Truist | Buy |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-08-30 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-31 | Iniziato | Credit Suisse | Neutral |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-04-29 | Iniziato | BTIG Research | Buy |
| 2020-01-21 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-11 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-11-14 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2018-05-08 | Iniziato | Robert W. Baird | Outperform |
| 2018-03-19 | Downgrade | JP Morgan | Overweight → Neutral |
Mostra tutto
Mersana Therapeutics Inc Borsa (MRSN) Ultime notizie
Can Traders Expect Breakout From Mersana Therapeutics Inc. This WeekStock Market Watch With Alerts Shows Unusual Activity - 선데이타임즈
Mersana Therapeutics Inc. Uptrend in Early Stages Indicators Say YesInvestment Plan With Growth Optimization Finalized - beatles.ru
Mersana Therapeutics MRSN 2025Q2 Earnings Preview Upside Ahead on Promising Drug Pipeline - AInvest
Revenues Working Against Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Share Price Following 25% Dive - simplywall.st
Is Mersana Therapeutics Inc. still worth holding after the dipAI-Based Reversal Point Prediction Signal - Newser
Will Mersana Therapeutics Inc. outperform the marketPattern Recognition Tool for ROI Investors - Newser
Will Mersana Therapeutics Inc. stock go up soonBuy and Hold Strategy for Capital Safety - Newser
Mersana Therapeutics Inc.’s volatility index tracking explainedFree Entry Alert Based on Volume Spikes - Newser
Competitive Positioning of Mersana Therapeutics Inc.: Is It Leading or LaggingGrowth Watchlist for Long Term Positioning - Newser
Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025 | MRSN Stock News - GuruFocus
Mersana Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025 - Quiver Quantitative
Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025 - GlobeNewswire
Leading Cancer ADC Developer Mersana Therapeutics Reveals Q2 2025 Earnings Date: Pipeline Updates Expected - Stock Titan
Mersana Therapeutics (NASDAQ:MRSN) Cut to “Strong Sell” at Wall Street Zen - Defense World
Ranking Mersana Therapeutics Inc. among high performing stocks via toolsTrading Volume Anomaly Summary and Insight - Newser
What are analysts’ price targets for Mersana Therapeutics Inc. in the next 12 monthsAchieve breakthrough gains with expert advice - Jammu Links News
Mersana Therapeutics Inc. Recovers — But Is It SustainableStock Portfolio Allocation Guidance for Volatile Markets - beatles.ru
Should I hold or sell Mersana Therapeutics Inc. stock in 2025Gain the edge with real-time market data - Jammu Links News
Why Mersana Therapeutics Inc. stock attracts strong analyst attentionFree Stock Selection With High Accuracy - Newser
Does Mersana Therapeutics Inc. stock perform well during market downturnsExponential return rates - Jammu Links News
What are the latest earnings results for Mersana Therapeutics Inc.Invest confidently with professional guidance - Jammu Links News
How does Mersana Therapeutics Inc. generate profit in a changing economyRapidly expanding wealth - Jammu Links News
When is Mersana Therapeutics Inc. stock expected to show significant growthCapitalize on strong market momentum - Jammu Links News
How does Mersana Therapeutics Inc. compare to its industry peersGet timely alerts on top-performing stocks - Jammu Links News
Why is Mersana Therapeutics Inc. stock attracting strong analyst attentionRapid market gains - Jammu Links News
How volatile is Mersana Therapeutics Inc. stock compared to the marketIdentify winners with top-tier analysis - Jammu Links News
What is the dividend policy of Mersana Therapeutics Inc. stockRetirement Planning Insights For 2025 - Jammu Links News
How strong is Mersana Therapeutics Inc. company’s balance sheetStock Strategy Insights For Fast Growth - Jammu Links News
How Mersana Therapeutics Inc. stock performs during market volatilityShort Term Alpha Signals Review - beatles.ru
Full technical analysis of Mersana Therapeutics Inc. stockPortfolio Positioning Strategy With Timing - Newser
Will Mersana Therapeutics Inc. benefit from macro trendsGrowth Based Investment Plan Guidance Highlighted - metal.it
Published on: 2025-07-30 03:04:39 - metal.it
Published on: 2025-07-29 23:14:19 - metal.it
Will Mersana Therapeutics Inc. stock split in the near futureBreakout Stocks Insights To Watch Now - Jammu Links News
Mersana Therapeutics Inc. Sees Spike in Bullish Option FlowStable Entry High Return Opportunities in Focus - beatles.ru
Is Mersana Therapeutics Inc. a Top Dividend Stock to Watch in 2025Watchlist for Low Risk High Return Stocks Updated - metal.it
Top Risks to Consider Before Buying Mersana Therapeutics Inc. Stock Oversold Reversal Picks with Buy Zone - metal.it
What is Mersana Therapeutics Inc. company’s growth strategyUnmatched market performance - jammulinksnews.com
MRSN Trading Halted Due to Pending News - GuruFocus
What analysts say about Mersana Therapeutics Inc. stockSuperior stock selection - PrintWeekIndia
Mersana Therapeutics Inc Azioni (MRSN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Mersana Therapeutics Inc Azioni (MRSN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Mandelia Ashish | VP, Chief Accounting Officer |
Jan 16 '25 |
Sale |
0.58 |
3,554 |
2,061 |
57,519 |
| Protopapas Anna | Director |
Jan 15 '25 |
Option Exercise |
0.00 |
21,250 |
0 |
176,678 |
| Protopapas Anna | Director |
Jan 16 '25 |
Sale |
0.58 |
8,637 |
5,009 |
168,041 |
| Lowinger Timothy B | SVP, Chief Sci.&Tech. Officer |
Jan 15 '25 |
Option Exercise |
0.00 |
19,791 |
0 |
265,721 |
| Lowinger Timothy B | SVP, Chief Sci.&Tech. Officer |
Jan 16 '25 |
Sale |
0.58 |
8,048 |
4,668 |
257,673 |
| Huber Martin H. Jr. | President, CEO |
Jan 15 '25 |
Option Exercise |
0.00 |
11,062 |
0 |
127,389 |
| Huber Martin H. Jr. | President, CEO |
Jan 16 '25 |
Sale |
0.58 |
4,514 |
2,618 |
122,875 |
| DeSchuytner Brian | SVP, COO & CFO |
Jan 15 '25 |
Option Exercise |
0.00 |
20,833 |
0 |
129,863 |
| DeSchuytner Brian | SVP, COO & CFO |
Jan 16 '25 |
Sale |
0.58 |
8,470 |
4,913 |
121,393 |
| Carvajal Alejandra | SVP, Chief Legal Officer |
Jan 15 '25 |
Option Exercise |
0.00 |
12,500 |
0 |
83,392 |
0.81%
3.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):